Mounjaro label carries a four-week oral contraceptive warning semaglutide labels lack

When Mounjaro (tirzepatide) entered the U.S. market in 2022, its prescribing information carried an instruction that semaglutide products do not: women using oral hormonal contraceptives should switch to a non-oral method or add a barrier method for four weeks after starting the drug and for four weeks after every dose increase ^[1][2].

What the label says

The instruction sits in section 8.3 of the Mounjaro label, under "Females of Reproductive Potential": "Advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation" ^[1]. The label lists an initial U.S. approval of 2022, and its current version was revised in August 2026 ^[1].

Mounjaro's dosing schedule keeps that four-week window recurring. The recommended starting dose is 2.5 mg injected once weekly; the dose rises in 2.5 mg steps no sooner than every four weeks, up to a maximum of 15 mg weekly for adults ^[1]. Because each escalation starts a new four-week backup period, and steps are spaced at least four weeks apart, a patient moving up on schedule can spend much of the titration phase inside one of those windows ^[1].

The label ties the concern to how the drug moves through the digestive tract: Mounjaro delays gastric emptying and "has the potential to impact the absorption of concomitantly administered oral medications" ^[1]. The prescribing information does not put a number on how much that delay reduces oral contraceptive absorption, and it does not estimate an individual patient's risk of contraceptive failure ^[1]. The question of how tirzepatide and GLP-1 receptor agonists affect oral hormonal contraception has been examined in a review published in the Journal of the American Pharmacists Association ^[2].

How this differs from semaglutide

Mounjaro is tirzepatide, which acts on both GIP and GLP-1 receptors ^[1]. Ozempic, Wegovy and Rybelsus are semaglutide, a GLP-1 receptor agonist. The four-week contraception instruction appears in tirzepatide's label; semaglutide product labels do not carry the same instruction, a difference that the pharmacy review addresses by comparing tirzepatide with GLP-1 receptor agonists ^[1][2].

Why it matters for patients

For a patient who takes an oral contraceptive and starts tirzepatide or moves to a higher dose, the label's advice is to change contraceptive method or add a barrier method for a defined stretch of weeks ^[1]. That applies at the start of treatment and again at each step up, not once ^[1]. Because placebo-controlled data on contraceptive failure with tirzepatide have not been described in the prescribing information, how much real-world pregnancy risk the instruction is meant to offset is not quantified there ^[1].

It also means counseling is not identical across this drug class. Someone who received no contraceptive instructions while on semaglutide may get different guidance on tirzepatide, even though nothing about her own health has changed ^[1][2]. The label also states that, based on animal studies, tirzepatide may cause fetal harm ^[1].

The instruction sits in the use-in-specific-populations section rather than in a boxed warning or the warnings and precautions summary. The label's only boxed warning concerns thyroid C-cell tumors ^[1].

What happens next

No change to the four-week instruction has been announced. It is not listed among the label's recent major changes, which as of the August 2026 revision covered a pediatric indication (12/2025), major adverse cardiovascular events (08/2026), recommended dosage (08/2026), severe gastrointestinal adverse reactions (12/2025), diabetic retinopathy complications (08/2026) and pen-sharing language (01/2026) ^[1]. Whether regulators will revisit the contraceptive wording, or whether semaglutide labels will add similar language, has not been reported ^[1][2].